Immunome IMNM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$53.84M-29.3% | -$69.9M+12.9% | -$57.46M-22.0% | -$43.4M-20.1% | -$41.64M+67.8% | ||
| $603K-1.3% | $629K+39.8% | $589K+43.3% | $637K+16.0% | $611K+289% | ||
| $7.95M+39.5% | $7.89M+44.3% | $6.75M+37.9% | $5.35M+65.7% | $5.7M+164% | ||
| -$79K— | -$55K— | $0— | -$891K— | -$0— | ||
| $1.42M+137% | -$2.28M-125% | —— | -$4.95M— | -$3.81M-259% | ||
| $5.1M+199% | $42K— | —— | $3.6M— | $1.71M+169% | ||
| -$0+100% | —— | —— | -$4.02M-69.8% | -$2.93M-184% | ||
| $150K+30.4% | $147K+1.4% | $144K-10.0% | $83K-33.1% | $115K+8.5% | ||
| -$161K-160% | -$158K— | -$129K-69.7% | $183K+536% | -$62K-148% | ||
| -$58.64M-10.5% | -$47.95M-14.0% | -$40.51M-18.6% | -$49.4M-111% | -$53.06M-375% | ||
| $3M-18.1% | $4M+255% | $1.12M-27.5% | $905K-61.4% | $3.67M+69.4% | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $0-100% | $125M+317% | $60M— | $15M— | ||
| $9.01M+44.3% | —— | —— | —— | $6.25M-82.2% | ||
| -$12.02M-336% | $0— | $123.88M— | -$64.17M+21.4% | $5.09M+114% | ||
| $229K+7.5% | $0-100% | $45.47M+4,514% | $215K-75.0% | $213K+24.6% | ||
| -$135K-100% | $432.8M+2,055% | $45.39M+14,782% | $0-100% | $162.23M-26.1% | ||
| -$70.79M-162% | $380.84M— | $128.76M— | —— | $114.26M-33.2% | ||
| $0-100% | $0-100% | $816K-44.6% | $1.21M+242% | $818K+52.0% | ||
| —— | $2.5M-93.4% | $2.5M-93.4% | $2.5M-93.4% | $2.5M-93.4% | ||
| -$9.75M-14.4% | $5.7M+13,156% | —— | —— | -$8.52M-1,374% | ||
| -$161K-160% | -$158K— | -$129K-69.7% | $183K+536% | -$62K-148% | ||
| $5.1M+199% | $42K— | —— | $3.6M— | $1.71M+169% | ||
| $150K+30.4% | $147K+1.4% | $144K-10.0% | $83K-33.1% | $115K+8.5% | ||
| $9.01M+44.3% | —— | —— | —— | $6.25M-82.2% | ||
| $0-100% | $0-100% | $125M+317% | $60M— | $15M— | ||
| $364K-96.5% | $27.78M+6,846% | $919K+350% | $270K-42.4% | $10.49M-25.9% | ||
| $0-100% | $460.5M— | —— | —— | $172.5M-25.0% | ||
| —— | $0— | $0— | —— | —— | ||
| $1.13M+91.0% | —— | —— | $695K+8.3% | $592K-0.3% | ||
| -$0+100% | —— | —— | -$4.02M-69.8% | -$2.93M-184% | ||
| -$161K-160% | -$158K— | -$129K-69.7% | $183K+536% | -$62K-148% | ||
| —— | $0— | $0— | —— | —— | ||
| $0-100% | —— | —— | -$270K— | $270K— | ||
| $986K— | —— | —— | —— | $0-100% | ||
| —— | $0-100% | $0-100% | —— | —— | ||
| -$61.64M-8.7% | -$51.95M-20.3% | -$41.63M-16.6% | -$50.31M-95.4% | -$56.72M-325% | ||
| -$61.64M-8.7% | -$51.95M-20.3% | -$41.63M-16.6% | -$50.31M-95.4% | -$56.72M-325% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's cash flow data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.